Clinical Trial Update: CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates CBM588 in combination with nivolumab and ipilimumab for advanced or stage IV renal cell carcinoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• CBM588
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 1 | Status: COMPLETED